institutions and pharmaceutical and non-pharmaceutical industry is a promising strategic approach to promote sustainable clinical research capacity. The government vision is that beyond national boundaries, resource sharing and involvement of private players are key factors to mitigate the high burden of disease, nationally and regionally.

OC 8521 PRELIMINARY REPORT ON SAFETY OF CO-ADMINISTERED HUMAN HOOKWORM VACCINE CANDIDATES NA-APR-1 (M74)/ALHYDROGEL® AND NA-GST-1/ALHYDROGEL® IN GABONESE CHILDREN

¹Jeanot Fréjus Zinsou*, ¹Josiane Honpkhedji, ¹Dejon Agobe Jean Claude, ¹Bayodé R Adegbite, ¹Jean Ronald Edoa, ²Remko Van Leeuwen, ³David Diemert, ⁴Maria Elena Botazzi, ⁵Peter G Kremsner, ⁶Maria Yazdanbakhsh, ⁴Peter Hotez, ²Martin P Grobusch, ¹Ayola Akim Adegnik, ²Sophie De Vries. ¹Centre de Recherches Médicales de Lambaréné, Gabon; ²Academic Medical Center, University of Amsterdam, The Netherlands; ³George Washington University School of Medicine and Health Sciences, USA; ⁴Baylor College of Medicine and Texas Children's Hospital, USA; ⁵Institut für Tropenmedizin, Universität Tübingen, Germany; ⁶Leiden University Medical Center, The Netherlands

10.1136/bmjgh-2019-EDC.28

Background Human hookworm infection is a major public health issue in tropical low and middle-income countries with severe consequences. To date, improvement of water supply, sanitation, and hygiene is the major contributor to disease control, and additional control tools are needed. Here, we assess a phase I trial of a new hookworm vaccine candidate Na-APR-1 (M74)/Alhydrogel and Na-GST-1/Alhydrogel in Gabonese school-age children.

Methods A double-blind, randomised, controlled, dose-escalation phase I clinical trial that aims to evaluate safety, reactogenicity and immunogenicity of Na-APR-1 (M74)/Alhydrogel co-administered with Na-GST-1/Alhydrogel hookworm vaccines in children aged 6 to 10 years living in hookworm-endemic area of Lambaréné, compared to the hepatitis B vaccine (ENGERIX-B). Children received three doses of assigned vaccines, delivered intramuscularly (deltoid) on Days 0, 56, and 112 or 180. Safety is measured from Day 0 through Day 14 by the occurrence of solicited injection site and systemic reactogenicity events. Clinical laboratory evaluations were performed approximately 14 days after each immunisation. Unsolicited adverse events were collected from Day 0 through approximately 1 month after each vaccination.

Results A total of 135 children were screened, and 60, aged 6 to 10 years old, were randomised into 3 groups and received 10 µg, 30 µg or 100 µg of Na-APR-1 (M74)/Alhydrogel and Na-GST-1 Alhydrogel, respectively, compared to ENGERIX-B. At baseline, the mean age of the study population was 7.4 years and the sex ratio 1.3 (male: female). From Day 0 up to Day 14 after vaccination, the main solicited adverse events were pain and swelling at injection sites with 135 (26 of grade 2 and 1 of grade 3) and 9 events, respectively. Regarding systemic adverse events, 3 occurrences of grade 1 headache were recorded. Immunogenicity analyses are underway.

Conclusion The preliminary results confirm that co-administration of the two hookworm vaccine candidates is safe and well-tolerated in Gabonese children.

OC 8535 AN OVERVIEW OF RESEARCH ETHICS COMMITTEES OPERATING IN LUSOPHONE AFRICAN COUNTRIES

¹Maria Rosário Oliveira Martins*, ²João Schwalbach, ^{2,3}Esperança Sevene, ⁴Antonieta Martins, ⁵Ema Candida Branco Fernandes, ⁴Isabel Ines Araujo, ⁶Helena Pereira De Melo, ²Amílcar Bernardo Tome Da Silva, ²Emanuel Catumbela, ³Jahit Sacarlal, ¹Jorge Seixas, ⁵Maria Chimpolo, ²Rassul Nala, ⁵Maria Tazi Nimi, ⁷Amabelia Rodrigues. ¹Global Health and Tropical Medicine Institute, Universidade NOVA de Lisboa, Portugal; ²Comité Nacional de Bioética para a Saúde de Moçambique; ³Universidade Eduardo Mondlane, Maputo, Mozambique; ⁴Universidade de Cabo Verde, Praia, Cape Verde; ⁵Faculdade de Medicina, Universidade Agostinho Neto, Comité Independente de Ética da Angola; ⁶Faculdade de Direito, Universidade Nova de Lisboa, Conselho de Ética da Universidade NOVA, Portugal; ⁷Projeto Saúde Bandim, Statens Serum Institut, Guiné-Bissau

10.1136/bmjgh-2019-EDC.29

Background In 2017, a North-South partnership was created, to strengthen Bioethics Committees in African Lusophone African countries (LAC), by joining the forces of National and Institutional Research Ethics Committees (REC) and Universities in Angola, Cape Verde, Mozambique and Portugal. This study is part of an EDCTP2-funded project and aims to describe key RECs operating in LAC, its establishment dates and further characteristics.

Methods Document analysis and interviews with REC representatives of five LAC were conducted in April 2018. Legal documents were obtained through official national sources.

Results We identified four National Ethics Committees, created between 2000 and 2008 by ministerial or governmental decree; only S. Tomé e Príncipe does not have an established REC. In Angola, the National REC was created in 2000, and since 2007, seven Institutional Committees were implemented at faculty level. National REC in Cape Verde and Guinée-Bissau (CNES) are unique and were founded in 2007 and 2009 respectively. In Mozambique, National REC (CNBS) dates to 2002, and since 2011, 8 Institutional Committees were formed; they functioned as a network under the umbrella of CNBS. Most National REC have representatives from health professional associations, lawyers, civil society and religious communities and have regular meetings (usually monthly). The number of members ranges between 6 (CNES) and 13 (CNBS). In 2007, around 200 protocols were reviewed by CNBS and 29 by CNES. Most of the National REC members attended training activities in bioethics but at different levels.

Conclusion Few publications described REC operating in LAC; this study fills this gap by reporting historical and functional characteristics of RECs in five Lusophone African countries. Additional tools based on quantitative and qualitative approaches are being developed to assess more in-depth REC operational characteristics and to identify their needs in order to target training and capacity building initiatives underlying our project.

OC 8546 SAFETY AND IMMUNOGENICITY OF THE MALARIA VACCINE CANDIDATE BK-SE36 IN YOUNG CHILDREN LIVING IN BURKINA FASO

¹Sodiomon Sirima, ¹Alfred B Tiono, ²Sophie Houard, ¹Edith C Bougouma, ¹Sam A Coulibaly, ²Odile Leroy, ³Nirianne Palapac, ³Toshihiro Horii, ¹Issa N Ouedraogo. ¹Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso; ²European Vaccine Initiative, Universitäts Klinikum Heidelberg, Germany; ³Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Japan

10.1136/bmjgh-2019-EDC.30

Background The malaria blood stage vaccine candidate SE-36 is based on the serine repeat antigen of *Plasmodium*

falciparum. Epidemiological studies have shown that antibodies against SE36 correlate with lower parasitaemia in Solomon Island residents. In a phase I b trial conducted in Uganda, the BK-SE36 vaccine, SE36 formulated with aluminium hydroxide gel, was found safe and immunogenic. Interestingly, highest levels of IgG anti-SE36 protein associated with protection against severe malaria were found in the youngest Ugandan trial participants.

Objectives To assess the safety and immunogenicity of the BK-SE36 vaccine in a randomised controlled double-blind age de-escalating phase Ib clinical trial in younger (≤ 5 years) malaria-exposed children living in Burkina Faso.

Methods Healthy participants (108) were included in two age cohorts, one consisting of 54 children aged 25–60 months and the other of 54 children aged 12–24 months. Trial participants received 3 intramuscular or subcutaneous injections of the BK-SE36 vaccine at Day 0, Week 4 and 26. Participants allocated to the control group received the control Synflorix vaccine via intramuscular route at Day 0 and Week 26 and saline at Week 4. The participants were followed for one year. Immune responses were evaluated by ELISA, ELISpot and parasite carriage by microscopy and PCR.

Results Preliminary data from an interim analysis (data collected one month after the last immunisation) indicated that the vaccine was safe, well-tolerated and induced an IgG anti-SE36 response in these younger populations. The trial's latest safety, immunogenicity and preliminary efficacy results will be presented.

OC 8552 EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5–17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO

¹Alfred B Tiono*, ¹Issa Nebie, ²Nicholas Anagnostou, ¹Sam A Coulibaly, ²Alison Lawrie, ¹Edith C Bougouma, ¹Alphonse Ouedraogo, ¹Jean Baptist Yaro, ¹Aissata Barry, ²Rachel Roberts, ¹Amidou Ouedraogo, ²Katie J Ewer, ³Nicola K Viebig, ¹Amidou Diarra, ³Odile Leroy, ²Philip Bejon, ²Adrian Hill, ¹Sodiomon B Sirima. ¹Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso; ²Centre for Clinical Vaccinology and Tropical Medicine University of Oxford Churchill Hospital, UK; ³European Vaccine Initiative, Universitäts Klinikum Heidelberg, Germany

10.1136/bmjgh-2019-EDC.31

Background Heterologous prime-boost immunisation with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA)-vectored vaccines is a strategy previously shown to provide substantial protective efficacy against *P. falciparum* infection in a UK adult phase IIa sporozoite challenge study, and in a trial in Kenyan adults.

Methods We conducted the first phase IIb clinical trial assessing the safety, immunogenicity and efficacy of ChAd63-MVA ME-TRAP in 700 healthy malaria exposed children aged 5–17 months in a highly malaria-endemic area of Burkina Faso.

Participants were randomly assigned to received either ChAd63 ME-TRAP followed eight weeks later by MVA ME-TRAP or 2 doses of rabies vaccine. Monitoring of solicited adverse events was performed for seven days after each vaccination. Unsolicited adverse events were recorded until one month post each vaccination. Serious adverse events and malaria episodes were monitored throughout the study duration. Blood samples were collected at predefined timepoints to assess vaccine immunogenicity.

Results ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses [median

326 SFU/106 PBMC (95% CI 290–387)]. However, non-significant low efficacy was observed against clinical malaria during the follow-up period, with efficacy against primary endpoint estimated by proportional analysis being 10.7% (95% CI: –44.2 to 44.7%) at sixth months post MVA ME-TRAP and 3.1% (95% CI –15.0 to 18.3; $p=0.72$) by cox regression.

Conclusion This study has confirmed ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in children and infants with prior exposure to malaria. No significant protective efficacy was observed in this highly endemic context.

OC 8561 RAPAED TB: AN INNOVATIVE CHILD TB DIAGNOSTIC VALIDATION STUDY

¹Laura Olbrich*, ²Heather Zar, ³Steve Graham, ⁴Issa Sabi, ⁴Nyanda E Ntinginya, ⁵Nilesh Bhatt, ⁶Marriott Nliwasa, ⁷Elizabeth Corbett, ⁸Rinn Song, ⁹Claudia Denking, ¹Michael Hölscher, ¹Norbert Heinrich. ¹University of Munich (LMU), Germany; ²Red Cross War Memorial Children's Hospital, MRC Unit on Child and Adolescent Health Unit, Cape Town, South Africa; ³University of Melbourne, Australia; ⁴NIMR-Mbeya Medical Research Programme, Dar es Salaam, Tanzania; ⁵Instituto Nacional de Saúde (INS), Marracuene, Mozambique; ⁶Malawi College of Medicine, Blantyre Malawi; ⁷London School of Hygiene and Tropical Medicine, UK; ⁸Oxford Vaccine Group, University of Oxford, UK; ⁹Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

10.1136/bmjgh-2019-EDC.32

Background Children account for an estimated 1 million new cases of TB every year, representing roughly 7% of the total disease burden. Every year, around 2 09 000 children die from TB, half of those cases are in Africa. The main issue continues to be timely and accurate diagnosis, as treatment outcomes – even in the case of drug resistance – are significantly better than in adults.

Clinical diagnosis in the absence of laboratory confirmation is hampered by non-specificity of symptoms. Diagnostics validation studies in children are difficult – in most studies, very few of the symptomatic children achieved microbiological disease confirmation, resulting in imprecise estimates for test sensitivity.

Design/methods With the RaPaed TB study funded by EDCTP, we are preparing an improved diagnostic validation study design to improve on the traditional approach of a single-gate, double diagnostic study in the target population. The project will evaluate multiple new tests on the same patients, to determine algorithms of screening and confirmatory tests. Most novel tests in this study use non-sputum samples and are therefore more suitable for children.

Allocation of patients to standardised groups will follow the recommendations of the NIH-convened consensus panel on case definitions of paediatric TB diagnostic studies. Using an endpoint review committee will allow blinded review of those new-positive cases, plus matched controls, and determine their likelihood of disease based on clinical data including follow-up, and X-ray. This will improve the quality of evaluation of false positive vs. true positive results of new tests and therefore improve the assessment of specificity.

To improve on sensitivity assessment, the study includes partners with a high number of confirmed cases in past studies and plans to draw in cases of confirmed disease from other diagnostic facilities.

Conclusion This improved methodology will lead to more meaningful and applicable results of diagnostic validation studies.